Close Menu

NEW YORK (GenomeWeb) — Cancer diagnostics developer Precipio said today that it will implement a 1-for-15 reverse stock split in a bid to regain compliance with a Nasdaq listing requirements.

In a filing with the US Securities and Exchange Commission, New Haven, Connecticut-based firm said that it received notice late last month that it did not meet the exchange's $1 minimum bid price requirement and that its stock was facing delisting.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.